.png)
Most 340B federal grantees know, in general terms, that their program is generating revenue. What fewer organizations can answer precisely is how much revenue they should be generating versus how much they are actually capturing. The gap between those two numbers is almost never zero, and in many cases, it is larger than leadership expects.
The reasons revenue disappears are rarely dramatic. There is no single moment of failure, no obvious error that triggers a loss. Instead, revenue erodes quietly through eligibility determinations that miss qualifying patients, contract pharmacy arrangements that no longer function the way they were designed, and registration gaps that silently exclude entire sites from program participation. Each gap looks manageable in isolation. Together, they represent a meaningful and ongoing reduction in the financial benefit the 340B program is supposed to deliver.
This article examines three of the most common sources of hidden revenue loss for 340B federal grantees, and what compliance teams and organizational leaders can do to find them before an auditor does.
The Two Directions Eligibility Errors Run
When compliance teams think about eligibility errors, they typically think about the risk of over-inclusion, patients being flagged as 340B-eligible when they should not be. That is a real and serious compliance risk. But there is an equally common problem that receives far less attention: under-inclusion, where patients who do qualify for 340B are not being captured, and the organization is purchasing drugs for them at full price when it did not need to.
Both types of errors cost the organization. Over-inclusion creates repayment liability and audit exposure. Under-inclusion means the program is not delivering the revenue it should. For most grantees, both are happening simultaneously, and neither is visible without deliberate analysis of claims data against eligibility records.
How Restrictions Create Revenue Loss
Over the past several years, a significant number of drug manufacturers have imposed restrictions on the contract pharmacy arrangements that covered entities can use to access 340B pricing. The restrictions vary by manufacturer but commonly limit a grantee to a single designated contract pharmacy per manufacturer, or in some cases restrict access entirely for entities that have an in-house pharmacy option, even if that option is not practical for the patient population being served.
For grantees who rely on contract pharmacies as their primary or sole dispensing channel, these restrictions translate directly into revenue loss. When a manufacturer’s restriction prevents a 340B-eligible prescription from being filled at a 340B price, the drug is purchased at the contract or WAC price instead. The prescription still gets filled. The patient still receives the drug. But the financial benefit that was supposed to flow back to the organization does not.
The Registration Requirement Most Organizations Underestimate
For 340B federal grantees, any site that intends to purchase or dispense 340B drugs must be registered and approved in OPAIS before 340B activity can begin at that location. Registration is not retroactive, and eligibility to use 340B pricing does not attach until HRSA approval becomes effective.
This requirement appears straightforward, but in practice it is frequently underestimated. The operational gap between when a site begins seeing patients and when OPAIS registration becomes active is a common source of exposure in grantee programs.
The compliance implications are clear. If 340B drugs are purchased or dispensed through a site prior to its effective registration date, those transactions may be subject to repayment.
The financial implications are less obvious but equally significant. When a site is open and treating patients but not yet registered in OPAIS, prescriptions written there may be filled outside the 340B program, resulting in missed revenue. In other cases, 340B pricing may be applied before authorization is effective, creating audit risk and repayment liability instead of revenue.
In most situations, this is not the result of intentional misuse. More often, it reflects a breakdown in coordination between operations, compliance, and 340B oversight. For grantees, whose eligibility is tied to specific, in-scope service delivery sites, OPAIS functions as the formal authorization record of where 340B activity is permitted. When operations move faster than registration, exposure follows.
Each of the three gaps described above shares a common characteristic: they are not detectable through normal program operations. Your financial reports will not surface uncaptured claims. Your TPA dashboard will not show you manufacturer restriction leakage. Your internal site list will not flag OPAIS discrepancies. Finding these gaps requires deliberate, structured analysis that most compliance teams do not have the bandwidth or the specialized tools to perform on their own.
That is not a criticism, it is a reality of how complex the 340B program has become. The regulatory environment has grown significantly more demanding over the past few years, and the gap between what a well-resourced compliance program looks like and what most grantees have in place has grown with it.
For organizations that have not had an independent review of their 340B program in the past twelve to eighteen months, the question is not whether gaps exist. It is how large they are and how long they have been accumulating. A qualified 340B consultant can conduct a structured program assessment that identifies revenue leakage, flags compliance exposure, and gives your team a clear picture of where your program stands, before an auditor provides one for you.
